BACKGROUND: Radial artery access for coronary angiography and interventions has been promoted for reducing hemostasis time and vascular complications compared with femoral access, yet it can take longer to perform and is not always successful, leading to concerns about its cost. We report a cost-benefit analysis of radial catheterization based on results from a systematic review of published randomized controlled trials. METHODS AND RESULTS: The systematic review added 5 additional randomized controlled trials to a prior review, for a total of 14 studies. Meta-analyses, following Cochrane procedures, suggested that radial catheterization significantly increased catheterization failure (OR, 4.92; 95% CI, 2.69-8.98), but reduced major complications (OR, 0.32; 95% CI, 0.24-0.42), major bleeding (OR, 0.39; 95% CI, 0.27-0.57), and hematoma (OR, 0.36; 95% CI, 0.27-0.48) compared with femoral catheterization. It added approximately 1.4 minutes to procedure time (95% CI, -0.22 to 2.97) and reduced hemostasis time by approximately 13 minutes (95% CI, -2.30 to -23.90). There were no differences in procedure success rates or major adverse cardiovascular events. A stochastic simulation model of per-case costs took into account procedure and hemostasis time, costs of repeating the catheterization at the alternate site if the first catheterization failed, and the inpatient hospital costs associated with complications from the procedure. Using base-case estimates based on our meta-analysis results, we found the radial approach cost $275 (95% CI, -$374 to -$183) less per patient from the hospital perspective. Radial catheterization was favored over femoral catheterization under all conditions tested. CONCLUSIONS: Radial catheterization was favored over femoral catheterization in our cost-benefit analysis.
BACKGROUND: Radial artery access for coronary angiography and interventions has been promoted for reducing hemostasis time and vascular complications compared with femoral access, yet it can take longer to perform and is not always successful, leading to concerns about its cost. We report a cost-benefit analysis of radial catheterization based on results from a systematic review of published randomized controlled trials. METHODS AND RESULTS: The systematic review added 5 additional randomized controlled trials to a prior review, for a total of 14 studies. Meta-analyses, following Cochrane procedures, suggested that radial catheterization significantly increased catheterization failure (OR, 4.92; 95% CI, 2.69-8.98), but reduced major complications (OR, 0.32; 95% CI, 0.24-0.42), major bleeding (OR, 0.39; 95% CI, 0.27-0.57), and hematoma (OR, 0.36; 95% CI, 0.27-0.48) compared with femoral catheterization. It added approximately 1.4 minutes to procedure time (95% CI, -0.22 to 2.97) and reduced hemostasis time by approximately 13 minutes (95% CI, -2.30 to -23.90). There were no differences in procedure success rates or major adverse cardiovascular events. A stochastic simulation model of per-case costs took into account procedure and hemostasis time, costs of repeating the catheterization at the alternate site if the first catheterization failed, and the inpatient hospital costs associated with complications from the procedure. Using base-case estimates based on our meta-analysis results, we found the radial approach cost $275 (95% CI, -$374 to -$183) less per patient from the hospital perspective. Radial catheterization was favored over femoral catheterization under all conditions tested. CONCLUSIONS: Radial catheterization was favored over femoral catheterization in our cost-benefit analysis.
Authors: William F Fearon; Bernhard Bornschein; Pim A L Tonino; Raffaella M Gothe; Bernard De Bruyne; Nico H J Pijls; Uwe Siebert Journal: Circulation Date: 2010-11-29 Impact factor: 29.690
Authors: Stephan Achenbach; Dieter Ropers; Lisa Kallert; Nesrin Turan; Robert Krähner; Tobias Wolf; Christoph Garlichs; Frank Flachskampf; Werner G Daniel; Josef Ludwig Journal: Catheter Cardiovasc Interv Date: 2008-11-01 Impact factor: 2.692
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann Journal: BMJ Date: 2008-04-26
Authors: Nathaniel R Smilowitz; Ajay J Kirtane; Michael Guiry; William A Gray; Pilar Dolcimascolo; Michael Querijero; Claudia Echeverry; Nellie Kalcheva; Braulio Flores; Varinder P Singh; Leroy Rabbani; Susheel Kodali; Michael B Collins; Martin B Leon; Jeffrey W Moses; Giora Weisz Journal: Am J Cardiol Date: 2012-04-04 Impact factor: 2.778
Authors: Sanjit S Jolly; Salim Yusuf; John Cairns; Kari Niemelä; Denis Xavier; Petr Widimsky; Andrzej Budaj; Matti Niemelä; Vicent Valentin; Basil S Lewis; Alvaro Avezum; Philippe Gabriel Steg; Sunil V Rao; Peggy Gao; Rizwan Afzal; Campbell D Joyner; Susan Chrolavicius; Shamir R Mehta Journal: Lancet Date: 2011-04-04 Impact factor: 79.321
Authors: Yangchun Li; Stephanie H Chen; Alejandro M Spiotta; Pascal Jabbour; Michael R Levitt; Peter Kan; Christoph J Griessenauer; Adam S Arthur; Joshua W Osbun; Min S Park; Nohra Chalouhi; Ahmad Sweid; Stacey Q Wolfe; Kyle M Fargen; Aaron S Dumont; Travis M Dumont; Marie-Christine Brunet; Samir Sur; Evan Luther; Allison Strickland; Dileep R Yavagal; Eric C Peterson; Clemens M Schirmer; Oded Goren; Shamsher Dalal; Gregory Weiner; Axel Rosengart; Daniel Raper; Ching-Jen Chen; Peter Amenta; Tyler Scullen; Cory Michael Kelly; Christopher Young; Michael Nahhas; Eyad Almallouhi; Arunprasad Gunasekaran; Suhas Pai; Giuseppe Lanzino; Waleed Brinjikji; Mehdi Abbasi; David Dornbos Iii; Nitin Goyal; Jeremy Peterson; Mohammad H El-Ghanem; Robert M Starke Journal: J Neurointerv Surg Date: 2020-06-02 Impact factor: 5.836